Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
OLMA | US
0
0%
Healthcare
Biotechnology
31/03/2024
05/07/2024
10.67
10.65
10.73
10.29
Olema Pharmaceuticals Inc. a clinical-stage biopharmaceutical company focuses on the discovery development and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250 an estrogen receptor (ER) antagonist and a selective ER degrader which is in Phase 1/2 clinical trial for the treatment of recurrent locally advanced or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib ribociclib and alpelisib in Phase 1b/2 clinical trial for the treatment of recurrent locally advanced or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera Inc. and changed its name to Olema Pharmaceuticals Inc. in March 2009. Olema Pharmaceuticals Inc. was incorporated in 2006 and is headquartered in San Francisco California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
55.6%1 month
49.8%3 months
82.0%6 months
79.4%-
-
2.39
0.01
0.01
-3.33
-
-
-112.13M
596.81M
596.81M
-
-
-
-
-48.31
5.95
24.60
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
2.13
Range1M
4.30
Range3M
6.85
Rel. volume
0.40
Price X volume
4.09M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
UroGen Pharma Ltd | URGN | Biotechnology | 15.88 | 653.15M | 5.80% | n/a | -246.69% |
Sage Therapeutics Inc | SAGE | Biotechnology | 10.78 | 648.76M | 1.51% | n/a | 0.47% |
Pliant Therapeutics Inc. | PLRX | Biotechnology | 10.52 | 634.63M | -0.57% | n/a | 12.50% |
Humacyte Inc | HUMA | Biotechnology | 5.27 | 627.57M | -7.05% | n/a | 71.00% |
Scholar Rock Holding Corporation | SRRK | Biotechnology | 7.74 | 617.30M | -0.39% | n/a | 32.90% |
Savara Inc | SVRA | Biotechnology | 4.43 | 612.18M | 2.31% | n/a | 21.80% |
GH Research PLC Ordinary Shares | GHRS | Biotechnology | 11.75 | 611.33M | -2.49% | n/a | 0.43% |
Lexicon Pharmaceuticals Inc | LXRX | Biotechnology | 1.67 | 603.69M | 0.60% | n/a | 36.78% |
PHATHOM PHARMACEUTICALS INC. | PHAT | Biotechnology | 10.3 | 602.91M | 0.49% | n/a | -315.85% |
Travere Therapeutics Inc. | TVTX | Biotechnology | 7.89 | 600.66M | -0.63% | n/a | 545.44% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Ennis Inc | EBF | Building Products & Equipment | 21.25 | 552.16M | -0.75% | 13.68 | 1.15% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 4.48 | 428.47M | -2.40% | n/a | 138.85% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 25.77 | 412.92M | -1.68% | n/a | 322.60% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.74 | 369.15M | -2.49% | 14.12 | 86.68% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.36 | 324.63M | -2.40% | 10.10 | 0.00% |
Latham Group Inc. | SWIM | Building Products & Equipment | 2.74 | 316.67M | -3.52% | 75.75 | 80.81% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.55 | 298.02M | -0.34% | 8.24 | 25.57% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 26.52 | 294.97M | -4.29% | 17.47 | -562.47% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 12.93 | 209.56M | -2.78% | 8.94 | 15.44% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 44.59 | 128.20M | -4.23% | 7.40 | 89.91% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -3.33 | -2.43 | Cheaper |
Ent. to Revenue | - | 4,101.76 | - |
PE Ratio | - | 41.26 | - |
Price to Book | 2.39 | 22.34 | Cheaper |
Dividend Yield | - | 2.39 | - |
Std. Deviation (3M) | 82.00 | 76.52 | Par |
Debt to Equity | 0.01 | 0.51 | Cheaper |
Debt to Assets | 0.01 | 0.24 | Cheaper |
Market Cap | 596.81M | 3.77B | Emerging |